Provided by Tiger Trade Technology Pte. Ltd.

Propanc Biopharma, Inc.

0.2779
-0.1121-28.74%
Post-market: 0.2505-0.0274-9.86%19:59 EST
Volume:1.90M
Turnover:563.42K
Market Cap:3.71M
PE:-0.06
High:0.3495
Open:0.3401
Low:0.2570
Close:0.3900
52wk High:11.00
52wk Low:0.0002
Shares:13.36M
Float Shares:3.40M
Volume Ratio:1.55
T/O Rate:55.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.9510
EPS(LYR):-14.8490
ROE:-1236.83%
ROA:-427.27%
PB:0.26
PE(LYR):-0.02

Loading ...

Company Profile

Company Name:
Propanc Biopharma, Inc.
Exchange:
NASDAQ
Establishment Date:
2007
Employees:
2
Office Location:
302, 6 Butler Street,Camberwell,Victoria,Australia
Zip Code:
3124
Fax:
61 3 9882 9969
Introduction:
Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

Directors

Name
Position
James Nathanielsz
Chief Executive Officer and Director
Annie VanBroekhoven
Independent Director
Josef Zelinger
Independent Director
Joseph Himy
Independent Director
Julian Kenyon
Director

Shareholders

Name
Position
James Nathanielsz
Chief Executive Officer and Director
Jeannine Zimmerman
Chief Financial Officer